Combinations of Pharmacologic Smoking Cessation Treatments

This study has been completed.

First Received: July 3, 2001 Last Updated: January 20, 2009 History of Changes

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00018187

Purpose

The purpose of this study is to test the effectiveness of a combination of the drugs bupropion and mecamylamine along with a nicotine patch as a therapy for smoking cessation.

Condition	Intervention	Phase
Smoking	Drug: Bupropion Drug: Mecamylamine Drug: Nicotine Patch	Phase I

MedlinePlus related topics: Quitting Smoking Smoking

Drug Information available for: Mecamylamine Nicotine tartrate Bupropion hydrochloride Bupropion Nicotine polacrilex Mecamylamine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	Combinations of Pharmacologic Smoking Cessation Treatments

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	November 1998
Estimated Study Completion Date:	June 2001

Eligibility

Ages Eligible for Study:	20 Years to 40 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Subjects must be a smoker between 20 and 40 years old, have smoked at least 20 cigarettes per day for at least 2 years, wish to stop smoking and be in good general health

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018187

Locations

United States, California
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073

Sponsors and Collaborators

Department of Veterans Affairs

Investigators

Investigator:

Neil Hartman, M.D.

More Information

No publications provided

Study ID Numbers:	ADRD-011-98S
Study First Received:	July 3, 2001
Last Updated:	January 20, 2009
ClinicalTrials.gov Identifier:	NCT00018187 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Department of Veterans Affairs:

smoking cessation
bupropion
mecamylamine
nicotine

Study placed in the following topic categories:

Dopamine Uptake Inhibitors
Nicotine polacrilex
Neurotransmitter Agents
Cholinergic Antagonists
Nicotinic Agonists
Psychotropic Drugs
Mecamylamine
Cardiovascular Agents
Antihypertensive Agents

Cholinergic Agents
Smoking
Dopamine
Nicotine
Bupropion
Dopamine Agents
Peripheral Nervous System Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Cholinergic Agonists
Nicotinic Antagonists
Nicotinic Agonists
Physiological Effects of Drugs
Psychotropic Drugs
Mecamylamine
Cholinergic Agents
Habits
Smoking

Nicotine
Therapeutic Uses
Ganglionic Stimulants
Antidepressive Agents, Second-Generation
Antidepressive Agents
Ganglionic Blockers
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions
Autonomic Agents
Bupropion
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 07, 2009